Clinical Trials Browser

Phase 1/2 × Active not recruiting × Gefitinib × Clear all

NCT03122717 2026-04-29

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung